Kobayashi Y, Haruta T, Okura K, Kuroki S
Jpn J Antibiot. 1983 Jun;36(6):1313-6.
Clinical evaluation was made on cefotetan (CTT), a new cephamycin antibiotic, and the following results were obtained. Following 6 patients were treated with a daily dose of 31.0-47.5 mg/kg of CTT, which was given in 3 divided doses by an intravenous injection or a 1 hour drip infusion; 2 patients with cystitis (causative organism: E. coli and P. mirabilis, respectively), 3 with pyelonephritis (E. coli in 3) and 1 patient with Salmonella enteritis (S. typhimurium). CTT showed a remarkable therapeutic effect on cystitis and pyelonephritis but was ineffective against Salmonella enteritis. Neither adverse clinical reactions nor abnormal laboratory findings were noted. Based on the above results, CTT is considered to be an appropriate and useful new antibiotic in the treatment of bacterial infections, particularly urinary tract infections in children. The fact that longer duration of blood concentrations has made is possible to give this antibiotic in 2 divided doses will be of great practical benefit.
对新型头孢霉素类抗生素头孢替坦(CTT)进行了临床评估,结果如下。6例患者接受每日剂量为31.0 - 47.5mg/kg的CTT治疗,分3次静脉注射或1小时静脉滴注给药;其中2例膀胱炎患者(致病菌分别为大肠杆菌和奇异变形杆菌),3例肾盂肾炎患者(3例均为大肠杆菌),1例沙门氏菌肠炎患者(鼠伤寒沙门氏菌)。CTT对膀胱炎和肾盂肾炎显示出显著的治疗效果,但对沙门氏菌肠炎无效。未观察到不良临床反应和实验室检查异常结果。基于上述结果,CTT被认为是治疗细菌感染,尤其是儿童尿路感染的一种合适且有用的新型抗生素。血药浓度持续时间较长使得该抗生素可以分2次给药,这将具有很大的实际益处。